Key result
Review evaluates prophylactic antiarrhythmic therapy and recent amiodarone trials after myocardial infarction.
Why the study?
Many deaths among hospital survivors of acute myocardial infarction are due to sustained ventricular tachycardia and ventricular fibrillation, but the optimal prophylactic antiarrhythmic therapy remains uncertain.
Does prophylactic amiodarone therapy prevent death due to ventricular arrhythmias in hospital survivors of acute myocardial infarction?
Does prophylactic amiodarone therapy prevent death due to ventricular arrhythmias in hospital survivors of acute myocardial infarction?
This review discusses the role of prophylactic amiodarone therapy in preventing sudden cardiac death among post-myocardial infarction patients.
Answers are grounded in this paper and cite their sources.
Pilot data suggest amiodarone may lower post-MI cardiac mortality and arrhythmias; larger trials needed to confirm.
Many deaths among hospital survivors of acute myocardial infarction are due to sustained ventricular tachycardia and ventricular fibrillation. This has prompted the evaluation of prophylactic antiarrhythmic drugs and devices. Although it is widely agreed that antiarrhythmic treatment is useful, it is not certain which therapy provides optimal results. Increasing recognition of the efficacy of amiodarone has prompted the design of several trials of the drug. This paper focuses on primary prophylactic antiarrythmic therapy in the post-infarction setting and particularly on recent amiodarone trials.
No takes yet. Share an insight, caveat, or question.
JA Cairns (1998) conducted a review in Acute myocardial infarction. Amiodarone was evaluated. This review focuses on primary prophylactic antiarrhythmic therapy, particularly recent amiodarone trials, in the post-infarction setting.
Synapse has enriched 10 related papers. Consider them for comparative context: